← All trials
NCT02533336
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 9, 2015
- Primary completion
- Aug 31, 2016
- Completion date
- Mar 31, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 4917
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute for Medical Research, TanzaniaLead sponsor
- Brandeis UniversityCollaborator
- Kilimanjaro Christian Medical College, TanzaniaCollaborator
- National Institute for Medical Research, TanzaniaReponsible party - principal investigator
- University of LondonCollaborator
- United States Agency for International DevelopmentCollaborator
- Centers for Disease Control and Prevention (CDC)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.